According to research report the global Genome Engineering Market is projected to reach $11.7 billion by 2026 from USD 5.1 billion in 2021, at a CAGR of 18.2 % between 2021 and 2026.

The key factors propelling the growth of this market are rising government funding and growth in the number of genomics projects, high prevalence of infectious diseases and cancer, technological advancements, increasing production of genetically modified crops, and growing application areas of genomics.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000

The technology segment of the genome editing market is classified into CRISPR, TALEN, ZFN, antisense, and other technologies (PiggyBac, Flp-In, Adenine Base Editor (ADE), and Jump-In). The CRISPR segment is expected to command the largest share of the global genome editing market in. The large share of this segment can be attributed to the potential advantage of CRISPR is its ability to multiplex, that is, to use multiple guide RNAs in parallel to target multiple sites simultaneously in the same cell, making it easier to mutate multiple genes at once or engineer precise deletions in a genomic region.

By application, the genome editing market is segmented into cell line engineering, genetic engineering, and other applications (diagnostics and therapeutics). The cell line engineering segment is estimated to account for the largest share of the global market. Growing industry focus on stem cell research, increasing global awareness about stem cell therapies, and increasing funding from governments and private organizations are driving the growth of the cell line engineering segment.

By end user, the genome editing market is segmented into biotechnology & pharmaceutical companies, academic & government research institutes, and contract research organizations. The biotechnology & pharmaceutical companies segment is estimated to account for the largest share of the global genome editing market. The increasing prevalence of infectious diseases and cancer are driving research activities worldwide; this is expected to drive the demand for genome editing in biotechnology & pharmaceutical companies.

Request For Report Sample pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=231037000

North America is expected to dominate the global genome editing market. Factors such as increasing use of genetically modified crops, the development of gene therapy in the US, rising prevalence of infectious diseases and cancer, and rising availability of research grants and funding are propelling market growth in North America.

Some of the major players in the market are Thermo Fisher Scientific (US), Merck (Germany), Horizon Discovery Group (UK), GenScript (US), Sangamo BioSciences (US), Integrated DNA Technologies (US), Lonza Group (Switzerland), New England Biolabs (US), OriGene Technologies (US), Transposagen Biopharmaceuticals (US), Editas Medicine (US), and CRISPR Therapeutics (Switzerland).

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
[email protected]